EUVIMEDEUVIMED entdecken
Crossref

3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis

ABSALON D. GUTIERREZ, RASHEDEH ROSHANI, HEATHER M. HIGHLAND, DAYI BIAN, ELIZABETH FRANKEL, JENNIFER E. BELOW

Diabetes · 05.06.2026 · 75 (Supplement_1)

DOI: 10.2337/db26-3058-lb ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ABSALON D. GUTIERREZ und 5 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction and Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs), such as semaglutide, have revolutionized obesity, diabetes, and CV disease management. Although major clinical trials (STEP1, STEP2) have linked fasting circulating proteomic signatures to semaglutide’s benefits, specific molecular pathways underlying responses remain unknown. Here, we link circulating multi-omic profiles and oral minimal model (OMM)-derived indices to semaglutide therapy in a community-based Mexican-American cohort.

Methods

In this prospective longitudinal study, we analyzed circulating transcriptomic and proteomic (fasting and prandial) profiles in adults with prediabetes (n=101) before and after 12 weeks of semaglutide therapy. Participants underwent serial blood sampling over 4 hours following a standardized meal to derive OMM metabolic indices. Individuals with pre-existing diabetes, recent use of antidiabetic or glucotoxic agents, severe organ dysfunction, or pregnancy were excluded.

Results

Transcriptomic analysis revealed 71 significant differentially expressed genes (pFDR< 0.05), primarily enriched in pathways governing lipid metabolism and transport, immunoinflammatory responses, and cell structure/signaling. Proteomic profiling identified 13 fasting-state and 4 prandial-state significant proteins (pFDR < 0.05), which mapped to pancreatic function, digestive enzyme regulation, and immunoinflammatory modulation. Regarding OMM data, significant increases (p < 0.05) were seen in insulin sensitivity (Si) and total disposition index (DItotal), with nonsignificant increases in dynamic and static insulin release (φd, φs).

Conclusion

Semaglutide significantly alters metabolic and molecular signatures in Mexican-Americans with prediabetes. Further integration of these multi-omic profiles with OMM data will elucidate the pathways driving personalized therapeutic outcomes in this high-risk population. Disclosure A.D. Gutierrez: None. R. Roshani: None. H.M. Highland: None. D. Bian: None. E. Frankel: None. J.E. Below: None. Funding National Institutes of Health (R01DK127084)

Zitieren

APA

GUTIERREZ, A. D., ROSHANI, R., HIGHLAND, H. M., BIAN, D., FRANKEL, E., & BELOW, J. E. (2026). 3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3058-lb

Vancouver

GUTIERREZ AD, ROSHANI R, HIGHLAND HM, BIAN D, FRANKEL E, BELOW JE. 3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3058-lb

BibTeX
@article{GUTIERREZ2026,
  author = {GUTIERREZ, ABSALON D. and ROSHANI, RASHEDEH and HIGHLAND, HEATHER M. and BIAN, DAYI and FRANKEL, ELIZABETH and BELOW, JENNIFER E.},
  title = {3058-LB: Semaglutide-Induced Modulation of Multiomic Profiles and Oral Minimal Model-Derived Metrics in Mexican-Americans with Prediabetes: A Preliminary Analysis},
  journal = {Diabetes},
  year = {2026},
  volume = {75},
  number = {Supplement_1},
  doi = {10.2337/db26-3058-lb}
}
Kostenlos starten →